Celanese(CE)
Search documents
Celanese(CE) - 2024 Q1 - Quarterly Results
2024-05-08 20:41
May 8, 2024 In this document, the terms the "Company," "we" and "our" refer to Celanese Corporation and its subsidiaries on a consolidated basis. Exhibit 99.2 Purpose Presentation Use of Non-US GAAP Financial Measures Non-GAAP financial measures disclosed by management are provided as additional information to investors, analysts and other parties because the Company believes them to be important supplemental measures for assessing our financial and operating results and as a means to evaluate our financial ...
Celanese (CE) to Report Q1 Earnings: What's in the Offing?
Zacks Investment Research· 2024-05-07 13:46
Celanese Corporation (CE) is scheduled to release first-quarter 2024 results after the closing bell on May 8.The company surpassed Zacks Consensus Estimate for earnings in two of the last four quarters and missed twice, with the average being 5.2%.The company is expected to have benefited from cost-cutting and efficiency initiatives, as well as investments in high-return organic projects and acquisition synergies in the quarter to be reported. However, it is likely to have been challenged by issues such as ...
Analysts Estimate Celanese (CE) to Report a Decline in Earnings: What to Look Out for
Zacks Investment Research· 2024-05-01 15:05
Wall Street expects a year-over-year decline in earnings on lower revenues when Celanese (CE) reports results for the quarter ended March 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on May 8. On the other ...
Here's Why You Should Retain Celanese (CE) in Your Portfolio
Zacks Investment Research· 2024-04-12 14:36
Celanese Corporation (CE) is expected to gain from its cost and productivity actions, investments in high-return organic projects and synergies of acquisitions. However, it faces challenges from weak demand and customer destocking in certain end markets and pricing pressures.The company’s shares have gained 44.5% in a year against an 8.1% decline of its industry. Image Source: Zacks Investment ResearchLet’s find out why this Zacks Rank #3 (Hold) stock is worth retaining at the moment.Celanese Gains on Acqui ...
Celanese (CE) Achieves Milestones in the Acetyl Chain Business
Zacks Investment Research· 2024-04-11 14:26
Celanese Corporation (CE) recently reached significant milestones at its facilities in Clear Lake, TX, and Nanjing, China. These achievements will enhance the competitive cost position, sustainability and operational flexibility of its Acetyl Chain (AC) business to meet future demand growth.In March 2024, the company commenced operations at its new 1.3-million-ton Clear Lake acetic acid expansion, touted as the world's lowest-cost and lowest-carbon footprint acetic acid facility. This expansion builds upon ...
Celanese (CE) Up 39% in 6 Months: What's Driving the Rally?
Zacks Investment Research· 2024-04-03 12:56
Celanese Corporation’s (CE) shares have shot up 38.7% over the past six months. The company has also outperformed its industry’s rise of 23.2% over the same time frame. It has also trounced the S&P 500’s roughly 22.3% rise over the same period.Let’s dive into the factors behind this leading chemical and specialty materials maker’s stock price appreciation. Image Source: Zacks Investment ResearchCE Gains on Acquisitions & ProductivityCelanese, a Zacks Rank #3 (Hold) stock, is gaining from its productivity me ...
Celanese (CE) and Secarna Partner for Antisense Therapies
Zacks Investment Research· 2024-03-22 12:16
Celanese Corporation (CE) and Secarna Pharmaceuticals GmbH & Co. KG recently established a research collaboration to create long-acting implants delivering antisense oligonucleotides ("ASO").ASOs are synthetic compounds that target specific messenger RNA to block the creation of proteins involved in the progression of a variety of diseases, including cardiometabolic, central nervous system, oncologic and uncommon disorders. Antisense therapy is a novel, commercially validated therapeutic method. However, it ...
Why Is Celanese (CE) Up 10% Since Last Earnings Report?
Zacks Investment Research· 2024-03-21 16:36
It has been about a month since the last earnings report for Celanese (CE) . Shares have added about 10% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Celanese due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Celanese's Earnings and Revenues Miss Estimates in Q4C ...
Here's Why You Should Hold Onto Celanese (CE) Stock For Now
Zacks Investment Research· 2024-03-21 15:41
Celanese Corporation (CE) is benefiting from its cost and productivity actions, investments in high-return organic projects and synergies of acquisitions amid headwinds from weak demand and customer destocking in certain end markets and pricing pressures.Shares of this leading chemical and specialty materials maker are up 63.9% in a year compared with 32.3% rise of its industry. Image Source: Zacks Investment ResearchLet’s find out why this Zacks Rank #3 (Hold) stock is worth retaining at the moment.Acquisi ...
Celanese: Appetite For Acquisitions Remains
Seeking Alpha· 2024-03-11 00:36
castillodominici In an article called ‘the seed is planted, now watch returns grow’, the case was made Celanese (NYSE:CE) would grow returns after the acquisition of DuPont’s (DD) Mobility and Materials (M&M) and division. Against the backdrop of a challenging market environment, this acquisition did not yet bring what many hoped for. Or, as Robbert Quillen aptly noted decades ago: Good times are when people make debts to pay in bad times The acquisition was supposed to add approximately US$0.9Bn in EBI ...